Organisation mondiale de la santé (OMS) · Journal articles

Weekly Epidemiological Record, 2010, vol. 85, 22 [full issue]

Organisation mondiale de la santé
Voir le document original

Le texte intégral est hébergé par l’organisation qui le publie. lawenc.com indexe les métadonnées et renvoie vers la source officielle.

Texte intégral

– 2010

/

(SAGE)

(SAGE) 1

. . 2010 / 15 13

:

.(SAGE)

(SAGE)

– 2010 . 2015 .

(1 :

.

2010 .

.

1

http://www.who.int/immunization/sage/en/index.html, accessed May 2010).(

1

(2 . ( .( . ( ) ) )

(SAGE)

) 2010 .(

/ 2015

/ .2010 /

. . 2010

.

2010 .(SAGE) . .

/

26

2

(SAGE)

.

5 . (SAGE) .

.

strain

.

replacement

GAVI

. . .

. ) 3

(ProVac

2

. 2009 3

15 (SAGE)

2010

/

Vaccine

. . .

: .2010 ( 2011 . 58 72 )

2009

/ (AMC)

1500 .

.

2

Andrus JK et al. A model for enhancing evidence-based capacity to make informed policy decisions on the introduction of new vaccines in the Americas: PAHO's ProVac initiative. Public Health Reports, 2007, 122:811–816.

Nelson EAS et al. The role of national advisory committees in supporting evidence-based decision making for national immunisation programs. Vaccine, 2010, 28(Suppl. 1):A1–110 (also available from http://www.sciencedirect.com/science/issue/5188-2010-999719999.8998-1900719).

3

4

2010 Pfizer GlaxoSmithKline

/

/ .2013 / . (SAGE)

10≥ 10≥ 2010 /

30 30 2012

. .

2015

2011

) (DTP3) %70 . (

. ) 2015

2.6

2015 2010

(B

–B 5

41 ) [HPV] 4.2

47

18

(A . .2010

(2 . (3 .

(1 : . .

5 7.5 . 2008 %92 2009 2000 .2010 . 6

.

10

%75

2008

: .

.

(1 : (3 .2008 " (4 . (6 . (5 . . " (2 .

. .

(1 : (2 . . (3 .

7

. ) .( .

2009

. .

2008

. 13 7 . 4 .

2010

/

24

.

8

(SAGE) . .

(SAGE)

.

(SAGE)

. .

(AEFI)

" .

" .

. . 9

. ) .(

.

.

.

(SAGE)

.

10

(SAGE)

. .

GACVS 4

2009

/

(SAGE) . 52010 (PCV)1 (

/

25

GACVS DNA )

.

(SAGE) DNA

(PCV)1 PCV1 DNA

.Rotarix

5

36-29 ،2010 ،5 ‫ر‬ ‫ا‬ Global Advisory Committee on Vaccine Safety. Statement of the Global Advisory Committee on Vaccine Safety on Rotarix. Geneva, World Health Organization, 2010 , accessed http://www.who.int/vaccine_safety/topics/rotavirus/rotarix_statement_march_2010/en/index.html( May 2010).

4

11

(

50000 .(

) 60 )

(SAGE) GACVS Rotarix . .76 .

5 .

124 34 .( %64

. 90 ) . 106

6 7

‫ر‬ ‫ر‬

‫ا‬. 51/52, 2009, . 533–537. ‫ا‬. 32, 2007, . 285–296.

12

. 8 2005 . . . . 2011 /

.

.

.9

(SAGE)

.

.

PATH

Procedure for assessing the acceptability, in principle, of vaccines for purchase by United Nations agencies Geneva, World Health Organization, 2006 (WHO/IVB/05.19). (Also available at http://www.who.int/immunization/documents/WHO_IVB_05.19/en/index.html.) 9 ‫ إ‬/‫ن‬ 15 – 13 ‫ا ة‬ ‫ا‬ ‫ا‬ ‫ري ا‬ ‫ا اء ا‬ ‫ا ع‬، ‫ت وا اد ا‬ ‫وا‬ ‫ا‬ .2010 ، ‫ا‬ ‫ا‬ .‫ا‬ ، ،2010 (http://www.who.int/immunization/sage/previous_april2010/en/index1.html, accessed May 2010).

8

13

Health Systems Building Blocks

. 244 .

. . .

.

(SAGE

)

.

14

. ) B DTP [Hib] ) .( ( HPV ) : ( )

. . (SAGE ) .

(

)

. 2009 .10 /

(SAGE ) (SAGE )

10

532-517

،2009 ،50 ‫ر‬

‫ا‬

15

. 24 . 12

. 6 . . 6

6≤

.

. . . .

. 16

. (SAGE ) ( ) . .

3 ≤ . . . (SAGE ) : .

.

17

) (cocooning (SAGE ) .

(SAGE )

. .

. . (SAGE ) .

B

(SAGE ) . . 18

( (SAGE ) . .( )

)

RV144

rpg120 CRF-01E B

( .

) 11

1

.

: (2 .

. . intercurrent infections .

16395 (1 CD4+ T

125 (P=0.039)

%31.2 .

.

(74) . CD4+ T

51

11

11 Rerks-Ngarm S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. New England Journal of Medicine, 2009, 361:2209–2220. (Also available from http://content.nejm.org/cgi/content/full/NEJMoa0908492.)

19

. . .( %99 %33) CD4+ T

(1 ≥) (3 . ( 12 (2 . %60

.

RV144 . (SAGE ) .

21

20

/

.2010

/

23 .2010

(SAGE ) . . . .

(SAGE ) .2009 289 A(H1N1) H5N1

A(H5N1) 500 2009 (H1N1) 15 2003 / . . .

B

(SAGE ) .2990 ‫م‬ (H1N1)

21

. < .

350 <

570

.12% 70

1.37 %28 : .2009 /

2010 2010 /

/

.

2009 -(H1N1)

. / . 94 12

2010

Wood DJ, et al. Update on H1N1 vaccine immunogenicity, safety and effectiveness. Geneva, World Health Organization, 2010 (http://www.who.int/immunization/sage/Influenza_2_H1N1_vaccine_immunogenicity_D_Wood_SAGE_April_201 0.pdf,; accessed May 2010).

22

. .2010 . /

48 46 22

74

(SAGE ) 500000 250000 . .13 . ) 56.19 ( . ( %75 ) 2011 /

H1N1 .2010 / (SAGE ) . 13

(SAGE )

(SAGE )

Shindo N. Global seasonal influenza disease burden and implementation of WHA 56.19. Geneva, World Health Organization, 2010 (http://www.who.int/immunization/sage/Influenza_4_WHA56.19_N_Shindo_SAGE_April_2010.pdf, accessed May 2010).

23

H1N1 (SAGE ) H5N1 / .H1N1 .2010

(SAGE )

.

(SAGE ) . . (GRADE) (GRADE) . 24

2008

(GRADE) . (GRADE) .

. (SAGE )

.

GRADE )

(SAGE )

( . . . . GRADE

25

(SAGE ) GRADE

. . Bradford-Hill

(SAGE ) . .GRADE

(SAGE )

2015 .

2010

26

(SAGE )

.

.

(SAGE ) . . (1 : .( 6 ) 3 (2 (3 . 2012 2010

(4 . .

27

2010 . . 6

.

(SAGE )

. 1.4 .2012 2010

.

28

(SAGE ) 14

.2010

/

Polio vaccines and routine polio immunization in the pre-eradication era [draft]. Geneva, World Health Organization, 2010 (http://www.who.int/immunization/sage/WHO_position_paper_on_polio_vaccines__Draft_2_March_2010.pdf, accessed May 2010).

14

29

Informations clés
Type de document Journal articles
Date d'adoption
Source Organisation mondiale de la santé